Laura Demurtas

578 total citations
20 papers, 363 citations indexed

About

Laura Demurtas is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Laura Demurtas has authored 20 papers receiving a total of 363 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 6 papers in Cancer Research. Recurrent topics in Laura Demurtas's work include Colorectal Cancer Treatments and Studies (10 papers), Cancer Genomics and Diagnostics (4 papers) and Lung Cancer Treatments and Mutations (4 papers). Laura Demurtas is often cited by papers focused on Colorectal Cancer Treatments and Studies (10 papers), Cancer Genomics and Diagnostics (4 papers) and Lung Cancer Treatments and Mutations (4 papers). Laura Demurtas collaborates with scholars based in Italy, Belgium and Sweden. Laura Demurtas's co-authors include Mario Scartozzi, Marco Puzzoni, Riccardo Giampieri, Christian Cadeddu Dessalvi, Giuseppe Mercuro, Giovanna Piscopo, Martino Deidda, Valeria Pusceddu, Clelia Madeddu and Pina Ziranu and has published in prestigious journals such as Journal of Clinical Oncology, Scientific Reports and British Journal of Cancer.

In The Last Decade

Laura Demurtas

18 papers receiving 360 citations

Peers

Countries citing papers authored by Laura Demurtas

Since Specialization

Citations

This map shows the geographic impact of Laura Demurtas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laura Demurtas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laura Demurtas more than expected).

Fields of papers citing papers by Laura Demurtas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laura Demurtas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laura Demurtas. The network helps show where Laura Demurtas may publish in the future.

Co-authorship network of co-authors of Laura Demurtas

This figure shows the co-authorship network connecting the top 25 collaborators of Laura Demurtas. A scholar is included among the top collaborators of Laura Demurtas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laura Demurtas. Laura Demurtas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Hormone Receptor-Positive/HER2-Positive Breast Cancer: Hormone Therapy and Anti-HER2 Treatment: An Update on Treatment Strategies 2024 ·Journal of Clinical Medicine ·Chiara Tommasi, (unknown), (unknown), (unknown), (unknown), Benedetta Pellegrino, Nerina Denaro, Laura Demurtas, Mariele Dessì, (unknown), (unknown), (unknown), Mario Scartozzi, Antonino Musolino, Cinzia Solinas	9
2	Food security: the Mediterrean region's desynchronize agenda 2023 ·New Medit ·(unknown), Laura Demurtas	1
3	2P Role of neutrophil-to-lymphocyte ratio (NLR) in the outcome of NSCLC EGFR mutated 2021 ·Journal of Thoracic Oncology ·(unknown), (unknown), (unknown), (unknown), Nicole Liscia, (unknown), Annagrazia Pireddu, Laura Demurtas, Eleonora Lai, (unknown), Clelia Madeddu, Elena Massa, Giorgio Astara, Mario Scartozzi	1
4	BRCA-mutant pancreatic ductal adenocarcinoma 2021 ·British Journal of Cancer ·Eleonora Lai, Pina Ziranu, (unknown), (unknown), Andrea Pretta, (unknown), Silvia Camera, Nicole Liscia, Stefano Mariani, Mara Persano, (unknown), Clelia Donisi, Laura Demurtas, Valeria Pusceddu, Marco Puzzoni, Mario Scartozzi	37
5	Liquid biopsy-driven anti-EGFR rechallenge in patients with metastatic colorectal cancer. 2021 ·Journal of Clinical Oncology ·Stefano Mariani, Marco Puzzoni, Nicole Liscia, (unknown), Andrea Pretta, (unknown), (unknown), Mara Persano, (unknown), Clelia Donisi, (unknown), Eleonora Lai, Laura Demurtas, Pina Ziranu, Valeria Pusceddu, Marina Pisano, Grazia Palomba, Milena Casula, Giuseppe Palmieri, Mario Scartozzi	2
6	Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study 2020 ·Targeted Oncology ·Luca Faloppi, Marco Puzzoni, Andrea Casadei‐Gardini, Nicola Silvestris, Gianluca Masi, Giorgia Marisi, Caterina Vivaldi, Cosmo Damiano Gadaleta, Pina Ziranu, Maristella Bianconi, Cristian Loretelli, Laura Demurtas, Eleonora Lai, Riccardo Giampieri, Gennaro Galizia, Paola Ulivi, Nicola Battelli, Alfredo Falcone, Stefano Cascinu, Mario Scartozzi	14
7	New therapeutic targets in pancreatic cancer 2019 ·Cancer Treatment Reviews ·Eleonora Lai, Marco Puzzoni, Pina Ziranu, Andrea Pretta, (unknown), Stefano Mariani, Nicole Liscia, (unknown), (unknown), Mara Persano, Clelia Donisi, (unknown), (unknown), Annagrazia Pireddu, Laura Demurtas, Valeria Pusceddu, Silvia Camera, Francesco Sclafani, Mario Scartozzi	76
8	BRAF-mutant colorectal cancer, a different breed evolving 2018 ·Expert Review of Molecular Diagnostics ·Eleonora Lai, Andrea Pretta, (unknown), Stefano Mariani, Riccardo Giampieri, Laura Casula, Valeria Pusceddu, Pierpaolo Coni, Daniela Fanni, Marco Puzzoni, Laura Demurtas, Pina Ziranu, Gavino Faa, Mario Scartozzi	18
9	Medical management of malignant bowel obstruction: our center experience 2017 ·Annals of Oncology ·Giorgio Astara, Eleonora Lai, (unknown), (unknown), (unknown), Mariele Dessì, Silvia Camera, (unknown), (unknown), (unknown), Nicole Liscia, Andrea Pretta, Laura Demurtas, Pina Ziranu, Marco Puzzoni, Francesco Atzori, Valeria Pusceddu, Elena Massa, Clelia Madeddu, Mario Scartozzi	1
10	The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab 2017 ·British Journal of Cancer ·Laura Demurtas, Marco Puzzoni, Riccardo Giampieri, Pina Ziranu, Valeria Pusceddu, Alessandra Mandolesi, Chiara Cremolini, Gianluca Masi, Fabio Gelsomino, Carlotta Antoniotti, Cristian Loretelli, Fausto Meriggi, Alberto Zaniboni, Alfredo Falcone, Stefano Cascinu, Mario Scartozzi	18
11	The role of sidedness, EGFR gene copy number (GCN) and EGFR promoter methylation in RAS/BRAF wild type (WT) colorectal cancer (CRC) patients receiving irinotecan/cetuximab. 2017 ·Journal of Clinical Oncology ·Marco Puzzoni, Riccardo Giampieri, Laura Demurtas, Valeria Pusceddu, Alessandra Mandolesi, Luca Faloppi, Cristian Loretelli, Alberto Zaniboni, Alfredo Falcone, Stefano Cascinu, Mario Scartozzi	0
12	Prognostic neutrophil-to-lymphocyte ratio in head and neck cancer: A single center experience. 2017 ·Journal of Clinical Oncology ·Pina Ziranu, Elena Massa, Marco Puzzoni, Laura Demurtas, Clelia Madeddu, (unknown), (unknown), Giorgio Astara, (unknown), Valeria Pusceddu, Andrea Pretta, Mariele Dessì, Francesco Atzori, Eleonora Lai, (unknown), Nicole Liscia, (unknown), (unknown), Roberto Puxeddu, Mario Scartozzi	0
13	Tumor infiltrating lymphocytes in gastrointestinal tumors: Controversies and future clinical implications 2016 ·Critical Reviews in Oncology/Hematology ·Cinzia Solinas, (unknown), Laura Demurtas, Marco Puzzoni, (unknown), Gilberto Morgan, Riccardo Giampieri, Mario Scartozzi	36
14	The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following? 2016 ·Targeted Oncology ·Marco Puzzoni, Nicola Silvestris, Francesco Leone, Riccardo Giampieri, Luca Faloppi, Laura Demurtas, Emanuela Dell’Aquila, Donatella Marino, Oronzo Brunetti, Silvio Ken Garattini, Elena Ongaro, Giorgio Astara, L. Orgiano, Giuseppe Aprile, Daniele Santini, Mario Scartozzi	15
15	Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients 2016 ·Scientific Reports ·Riccardo Giampieri, Lisa Salvatore, Michela Del Prete, Tiziana Prochilo, (unknown), Cristian Loretelli, Fotios Loupakis, Giuseppe Aprile, Elena Maccaroni, Kalliopi Andrikou, Maristella Bianconi, Alessandro Bittoni, Luca Faloppi, Laura Demurtas, Rodolfo Montironi, Marina Scarpelli, Alfredo Falcone, Alberto Zaniboni, Mario Scartozzi, Stefano Cascinu	22
16	Second-line angiogenesis inhibition in metastatic colorectal cancer patients: Straightforward or overcrowded? 2016 ·Critical Reviews in Oncology/Hematology ·Riccardo Giampieri, Marta Caporale, Filippo Pietrantonio, Filippo de Braud, Francesca Negri, Francesco Giuliani, Valeria Pusceddu, Laura Demurtas, Angelo Restivo, Caterina Fontanella, Giuseppe Aprile, Stefano Cascinu, Mario Scartozzi	9
17	Pathophysiology of cardiotoxicity induced by nonanthracycline chemotherapy 2016 ·Journal of Cardiovascular Medicine ·Clelia Madeddu, Martino Deidda, Alessandra Piras, Christian Cadeddu Dessalvi, Laura Demurtas, Marco Puzzoni, Giovanna Piscopo, Mario Scartozzi, Giuseppe Mercuro	91
18	A single institution survey on prevalence and management of severe cancer pain in patients with cancer of different sites 2015 ·Annals of Oncology ·Marco Puzzoni, Elena Massa, Laura Demurtas, (unknown), (unknown), Mario Scartozzi	1
19	Clinical Outcome of Patients With Stage IV Colorectal Cancer Receiving Combination Chemotherapy Without Surgery As Initial Treatment 2015 ·Annals of Oncology ·Elena Massa, Marco Puzzoni, Laura Demurtas, (unknown), (unknown), (unknown), (unknown), Mario Scartozzi	2
20	The distinctive molecular, pathological and clinical characteristics ofBRAF-mutant colorectal tumors 2015 ·Expert Review of Molecular Diagnostics ·Mario Scartozzi, Riccardo Giampieri, Giuseppe Aprile, Donatella Iacono, Daniele Santini, Emanuela Dell’Aquila, Nicola Silvestris, Antonio Gnoni, Marta Bonotto, Marco Puzzoni, Laura Demurtas, Stefano Cascinu	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact